Rifampicin prophylaxis for throat carriage of *Haemophilus influenzae* type b in patients with invasive disease and their contacts

Gwendolyn L Gilbert, Shona J MacInnes, Isobel A Guise

Abstract

Objective—To determine rates of colonisation with *Haemophilus influenzae* type b among household contacts of children with invasive *H influenzae* type b disease; compliance among medical staff with recommendations for use of rifampicin prophylaxis; and effects of rifampicin treatment in *H influenzae* type b colonisation of patients and contacts.

Design—Prospective study of patients and their household contacts.

Setting—Royal Children's Hospital (the major paediatric hospital) in Victoria, Australia, with catchment population of 4.2 million, including 300 000 children aged under 5 years.

Subjects—234 patients (age range 6 weeks to 8 years) with 235 episodes of all types of invasive *H influenzae* type b disease admitted during 1988-9 and their contacts.

Main outcome measures—Positive cultures of *H influenzae* type b from throat swabs taken at admission and six weeks subsequently; recording of rifampicin prophylaxis.

Results—The percentage of patients with positive throat cultures fell from 69% (33/48) on day 1 of admission to 9% (4/47) after three days' treatment; at six weeks' follow up 32% (32/99) of patients who had not received rifampicin and 8% (5/61) who had, had positive throat cultures. Among household contacts, 33% (62/190) of children and 7% (25/359) of adults were colonised, and the colonisation rates were similar in contacts of patients with all types of *H influenzae* type b disease. Rifampicin prophylaxis was indicated in 85 families; in 34% it was not prescribed at all for contacts and in 41% not as recommended. The colonisation rates at follow up were significantly less in siblings given rifampicin (12%, 9/78), particularly in families in which all members were treated (3%), than in those in which they were not (36%) (odds ratio 21.5; 95% confidence interval 3.0 to 103.4).

Conclusions—The rate of throat colonisation with *H influenzae* type b was similar among siblings of children with all types of invasive *H influenzae* type b disease. Colonisation in contacts can be reduced by rifampicin prophylaxis, but some contacts remained colonised or were recolonised by the time of follow up. Medical staff complied poorly with current recommendations for rifampicin prophylaxis, which reduces its intrinsically limited value in preventing *H influenzae* type b disease.

Introduction

Although epidemics of invasive *Haemophilus influenzae* type b disease are rare, the incidence of the disease among susceptible close contacts of affected children is 500-600 times higher than in other children in the same age group.¹⁻⁴ Most secondary cases occur in the week after onset of disease in the index case; the risk is about 2% in contacts aged under 4 years and up to 5% in those aged under 2 years.^{1,3} If given appropriately, rifampicin

prophylaxis may eliminate throat carriage of *H influenzae* type b and reduce the risk of secondary disease in contacts.^{5,7} On the basis of these observations the American Academy of Pediatrics and the National Health and Medical Research Council (Australia), among other authorities, recommend that if the contact group (usually a family) includes a child aged under 4 years, the whole group receive rifampicin prophylaxis (National Health and Medical Research Council, report of the 100th session, 1985).⁸ Despite the significantly increased risk of *H influenzae* type b disease among close contacts, recognised secondary cases account for only 1-2% of cases, and rifampicin prophylaxis as recommended is time consuming; costly; and is associated with risk of side effects, possible development of rifampicin resistance by the organism, and, sometimes, failure to prevent disease.^{9,10}

Most contacts in whom *H influenzae* type b colonisation and secondary disease have been studied were of patients with meningitis. Among the relatively few contacts of patients with epiglottitis studied, the trend was towards lower rates of colonisation than among those of patients with meningitis.^{11,12} However, the recommendations for prophylaxis do not distinguish between contacts of patients with different types of *H influenzae* type b disease.⁷ Primary treatment of the invasive disease usually does not eliminate pharyngeal carriage of the organism by patients; after their discharge from hospital they are a potential source of bacteria for recolonisation of family contacts, unless they are also given rifampicin.^{13,14}

We performed a study to determine: (a) the rates of colonisation with *H influenzae* type b among household contacts of children with different types of invasive *H influenzae* type b disease in Victoria, Australia, where the proportion of cases of epiglottitis is high¹⁵; (b) the extent to which current recommendations for rifampicin prophylaxis are followed by medical staff in a large children's hospital; (c) the effects of treatment on *H influenzae* type b colonisation of patients and of rifampicin prophylaxis on colonisation in both patients and contacts.

Methods

This study was part of a prospective study of invasive *H influenzae* type b disease among children admitted to this hospital during 1988-9. Cases of invasive *H influenzae* type b disease were defined as previously described,¹⁵ by isolation of *H influenzae* type b from a normally sterile specimen or from the upper respiratory tract of patients with epiglottitis or by detection of *H influenzae* type b antigen in the urine or cerebrospinal fluid of a patient with clinically compatible disease.

As soon as possible after admission one or both parents were interviewed and asked to answer a questionnaire, which included detailed medical, family, and social histories (to be reported elsewhere). Throat swabs were taken from the patient and house-

Department of Microbiology and Infectious Diseases, Royal Children's Hospital, Parkville, Victoria 3052, Australia
Gwendolyn L Gilbert, MD, director
Shona J MacInnes, BSC, research assistant
Isobel A Guise, research nurse

Correspondence to: Professor G L Gilbert, Department of Clinical Microbiology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales 2145, Australia.

hold contacts while the patient was in hospital (if possible before rifampicin was given). If necessary, a research nurse visited the patient's home to collect the specimens. Follow up swabs were collected from the patient and household contacts during a visit to the family's home by the research nurse, about six weeks after the admission (usually at least four weeks after discharge).

Throat swabs were taken with a standard technique. The swab was placed into 1 ml of Levinthal broth and used immediately to inoculate solid medium or stored at 4°C for no more than 24 hours. After inoculation the broth was shaken vigorously to release secretions, and the swab was removed and used to inoculate in a circular fashion around the edge of an agar medium containing *H influenzae* type b antiserum and then discarded. With a sterile loop 1 µl of the remaining broth was inoculated on to the agar in streaks radiating from its centre.¹⁶ The medium was Levinthal agar containing bacitracin (0.25 g/l) and 5% hyperimmune burro antiserum (kindly provided by Dr M Glode, Children's Hospital, Denver, Colorado). The plates were examined after 24-36 hours' incubation at 35°C in 5% CO₂ and suspect colonies were subcultured and identified by their growth requirements for X and V factors and by slide agglutination with commercial *H influenzae* type b antiserum (Wellcome). Throat swabs were collected by house staff from some patients, mainly those with epiglottitis, in whom the swabs were taken at the time of intubation. These swabs were used to inoculate chocolate agar containing bacitracin. Suspect colonies were subcultured and identified as above. Isolates of *H influenzae* type b were tested for β lactamase production with a commercial nitrocefin disc (BBL) and for susceptibility to ampicillin, chloramphenicol, ceftriaxone, and rifampicin by a disc diffusion method; minimum inhibitory concentrations of these antibiotics for 120 isolates were subsequently determined by agar dilution.

Clinical staff caring for patients with invasive *H influenzae* type disease had access to recommendations for use of rifampicin through locally published reviews and newsletters, discussion in hospital clinical meetings, or by consultation with the infectious disease team or pharmacy department.^{17,18} We did not attempt to influence, directly, the prescribing of rifampicin to patients or their contacts, or both, during the study. Whether rifampicin was prescribed or not was determined from the patient's record and whether it had been taken by questioning the parents. The recommended dose was 20 mg/kg daily for four days.

Comparison of proportions were made using the χ² test or, when numbers were small, Fisher's exact test. Odds ratios and 95% confidence intervals were calculated with the Epistat statistical package.

Results

During the study period 234 patients were admitted with 235 episodes of *H influenzae* type b disease. Their ages ranged from 6 weeks to 8 years; 120 (51%) were aged under 2 years and 40 (17%) were aged over 4 years. The clinical manifestations were: meningitis (83 patients, one of whom had two episodes at ages 6 and 8 months; mean age 22.6 months); epiglottitis (94; mean age 37.1 months); pneumonia (18); cellulitis (17); bacteraemia (13); septic arthritis (6); and pericarditis, severe pharyngitis, and a thyroglossal cyst (one each). The mean age of patients with infections other than meningitis or epiglottitis was 26.6 months. Two patients with meningitis and one with epiglottitis died. Most patients (80%) were treated with chloramphenicol, including 73 (88%) of those with meningitis and 93 (99%) of those with epiglottitis (the only exception was a patient who died suddenly before receiving anti-

biotics). Eight patients with meningitis were treated with ceftriaxone and two with cefotaxime. Among patients with other infections, 21 (37%) were treated with chloramphenicol and 30 (53%) with amoxycillin (two patients had both); 41 patients had combinations of two different antibiotics and 16 patients three. The clinical details of these patients will be reported elsewhere.

All 120 isolates of *H influenzae* type b were susceptible to chloramphenicol, ceftriaxone, and rifampicin by disc diffusion testing; 33 (14%) isolates produced β lactamase and an additional two were resistant to ampicillin by disc diffusion testing but did not produce β lactamase.

Patients' throat swabs collected on admission—Throat swabs from 193 (82%) patients were cultured. *H influenzae* type b was isolated from the swabs of 10% (7/68) of patients with meningitis, 41% (33/80) of patients with epiglottitis, and 31% (14/45) of patients with other types of infection. The low isolation rate from patients with meningitis correlated with delay in collecting the specimens. The isolation rate was 69% when swabs were collected on the day of admission but only 9% for swabs taken after three days of parental antibiotic treatment (table I). Specimens were not collected from some patients, particularly those with infections other than meningitis and epiglottitis, until more than a week after admission.

A total of 63 (27%) of the 235 patients had had some oral antibiotic treatment before admission, including 32 of 84 (38%) with meningitis, 11 of 94 (12%) with epiglottitis, and 20 of 57 (35%) patients with other infections. Antibiotic treatment before admission did not appreciably affect the rate of isolation of *H influenzae* type b from the throat swab. In patients whose throats were swabbed positive cultures resulted in 14 of 51 (27%) of those who had had antibiotics and 40 of 142 (28%) who had not.

Initial throat swabs from contacts—Throat swabs were collected during the patient's admission from 166 mothers, 148 fathers, and 45 other adult household contacts; 15 (9%) mothers, six (4%) fathers, and four (9%) other adults (7% of all adult contacts) had positive cultures. One hundred and seventy eight (76%) of the patients had at least one sibling. Two children in one family had *H influenzae* type b disease: both had epiglottitis and presented within 24 hours of each other—that is, they were coprimary cases. Altogether, there were 292 siblings and 234 index patients in 233 families (mean 2.3 children per family, including the index patient); 92 (32%) of the siblings were aged under 4 years. The number and age distribution of siblings did not differ significantly between contacts of patients with meningitis, epiglottitis, and other types of infection (table II). Initial throat swabs were collected from 190 (65%) siblings and 13 (33%) were positive. The proportion of contacts with positive throat swabs did not differ significantly according to the type of disease in the index patient (table II).

Rifampicin "prophylaxis"—Table III summarises the use of rifampicin in household contacts of patients. Rifampicin was prescribed for some or all members of

TABLE I—Throat carriage of *H influenzae* type b in patients with invasive disease

Hospital day	Positive throat swabs/total cultured			
	Meningitis	Epiglottitis	Other infections	Total (%)
1	3/7	29/38	1/3	33/48 (69)
2	2/10	2/17	1/4	5/31 (16)
3	0/19	1/10	3/9	4/38 (11)
4-7	1/22	1/9	2/16	4/47 (9)
>7	1/9	0/6	6/12	7/27 (26)
Unknown	0/1	—	1/1	1/2
Total (%)	7/68 (10)	33/80 (41)	14/45 (31)	54/193

TABLE II—Throat carriage of *H influenzae* type b in siblings of patients with invasive disease

Disease	No of cases	No (%) with siblings	Total No of siblings	No (%) siblings aged <4 years	Positive throat swabs/No taken (%)
Meningitis	84	63 (75)	98	34 (35)	23/75 (31)
Epiglottitis	94	70 (74)	121	33 (27)	21/69 (30)
Other infections	57	45 (80)	73	25 (34)	18/46 (39)
Total	235	178 (76)	292	92 (32)	62/190 (33)

TABLE III—Use of rifampicin in families and contacts of patients with invasive *H influenzae* type b disease

	No (%) of families
Other children in family aged <4 years (n=85):	
Receiving rifampicin	
None	24 (28)
Patients only	5 (6)
Some or all contacts	56 (66)
No other children in family aged <4 years (n=149):	
Receiving rifampicin	
None	106 (71)
Patients only	25 (17)
Some or all contacts	18 (12)
Some or all contacts receiving rifampicin (n=74):	
All contacts and patient	44 (59)
Siblings only	9 (12)
Siblings and parents	8 (11)
Siblings and patient	13 (18)

66% of families in which there was a child, other than the index patient, under 4 years of age and in 12% of families in which there was not. In families for which it was prescribed the use of rifampicin was variable; it was prescribed for all members, including the index patient, in only 59%. Rifampicin was not prescribed for contacts in 34% (29/85) of families in whom it was indicated according to current recommendations; these included 25% (8/32) of families of patients with meningitis, 20% (6/30) of those with epiglottitis, and 65% (15/23) of those with other infections. The proportion of families of patients with infections other than meningitis and epiglottitis who were not given rifampicin (when it was indicated) was significantly higher than those of patients with either meningitis or epiglottitis ($p=0.006$; odds ratio 6.4, 95% confidence interval 2.0 to 21.1). Among 74 families in which rifampicin was prescribed for some or all members, 18 had no child aged under 4 years other than the index patient including 36% (14/38) of families of patients with meningitis, 11% (3/27) of those with epiglottitis, and 11% (1/9) of those with other infections.

Effect of rifampicin on throat carriage in patients and contacts—Positive throat swabs resulted from 34% (34/99) of swabs from patients who had not been given rifampicin and 8% (5/61) from those who had been given rifampicin ($p=0.0005$; 5.8, 2.0 to 18.1). In families in which no rifampicin was given or it was given only to the index patient the proportion of positive throat swabs from contacts did not differ between initial and follow up cultures (8% (16/209) initial and 7% (11/200) follow up swabs in adults and 40% (44/109) and 36% (39/108) respectively in children). Isolation of *H influenzae* type b from follow up swabs in adults, in those families in which rifampicin prophylaxis was given, was reduced from 7% to 2%. The initial colonisation rate was significantly lower among siblings given rifampicin than among those not (22%, 18/81 *v* 40%, 44/109; $p=0.01$; odds ratio 2.4, 95% confidence interval 1.2 to 4.8). This reflects the fact that in two thirds of families swabs were collected after at least one dose of rifampicin had been taken. The colonisation rate at follow up (12%, 9/78) was not significantly different from the initial rate in these patients ($p=0.06$) but was significantly lower than the follow up colonisation rate in siblings not given

rifampicin (36%, 39/108; $p<0.003$; odds ratio 4.3, 95% confidence interval 1.8 to 10.5). In the families in which all members received rifampicin only 3% (1/39) of children were colonised at follow up; among siblings who were given rifampicin but either whose parents or the index patient were not 21% (8/39) were colonised at follow up, which was not quite significantly different from that in children not treated with rifampicin (36%, 39/108; $p=0.053$).

Discussion

We assumed that pharyngeal colonisation with *H influenzae* type b precedes invasive disease. The isolation rate of only 70% from patients whose throat swabs were taken on the day of admission probably reflects the fact that a single swab is relatively insensitive for detecting colonisation, especially if cultured on chocolate agar containing bacitracin rather than anti-serum agar,^{16 19} and that many patients had been given at least one dose of intravenous antibiotic treatment (usually chloramphenicol) before the swab was taken. The rapid decrease in the proportion of patients with swabs giving positive results reflects the ability of chloramphenicol, particularly, to suppress throat colonisation²⁰; this presumably reduces the risk of nosocomial transmission of *H influenzae* type b to a negligible level after the first day of treatment. The fact that most patients with disease other than meningitis or epiglottitis were treated with amoxycillin (which is less active than chloramphenicol in suppressing colonisation with *H influenzae* type b) probably explains the relatively high colonisation rate after several days of treatment.²⁰

Colonisation rates of 40% in child contacts not given rifampicin and 7% in adult contacts were lower than those reported in some other studies.^{7 11 12} In one study 71% of patients aged under 4 years and 44% of 5-10 year olds were colonised.¹¹ The colonisation rate varies with household crowding.¹² Some reports suggested that carrier rates are lower in contacts of patients with epiglottitis than in those of patients with meningitis (39% *v* 56% in one study and 14% *v* 27% in another), although the numbers of patients with epiglottitis were too small to show significance.^{11 12} In this study colonisation rates in the contacts of patients with epiglottitis did not differ significantly from those of patients with meningitis or other infections.

The use of rifampicin in contacts varied considerably. It was not clear whether this was owing to misinterpretation of the guidelines or use of alternative protocols. Rifampicin was prescribed least frequently, when indicated, in contacts of patients with infection other than meningitis and epiglottitis, presumably because the bacterial aetiology was not immediately obvious. It was more likely to be given when not indicated in contacts of patients with meningitis, which may reflect greater anxiety associated with this disease. The results confirm the ability of rifampicin, if given as recommended, to eradicate throat colonisation by *H influenzae* type b in most of those treated.^{5-7 21} However, the fact that the colonisation rate was relatively high at follow up among siblings who were given rifampicin but exposed to untreated household contacts emphasises the risk of colonisation. Previous studies showed that the use of rifampicin can protect contacts of patients with invasive *H influenzae* type b disease but, because of the fairly small proportion of cases which are attributable to secondary spread, its use has little impact on the overall incidence of the disease.⁶ There were no secondary cases (and only one coprimary case) among the patients in this study. In a previous study of 547 cases of invasive *H influenzae* type b disease in Victoria, three pairs of siblings, all aged under 5 years, were affected. Rifampicin pro-

phylaxis had not been given to contacts of these patients, but only one of the "secondary" cases occurred within 30 days of the index case; the others were two months and three months apart. Although rifampicin prophylaxis is of limited value, the relatively poor compliance with the current recommendations suggests that its value is commonly reduced even further by incorrect use.

There has been concern that widespread use of rifampicin might lead to the development of rifampicin resistant strains of *H influenzae* type b.¹⁰ However, in our laboratory all of 120 strains of *H influenzae* type b tested by agar dilution were inhibited by <0.03 mg/l rifampicin (unpublished data). Other objections to the use of rifampicin are that it sometimes fails to prevent secondary *H influenzae* type b disease⁹ and that it is associated with significant cost and risk of toxicity. A four day course for a family of two adults and three children is \$A50 and the risk of toxicity is small if suitable precautions are observed. At present there is no alternative to rifampicin for contacts in whom its use is contraindicated—for example, pregnant women. Ceftriaxone is effective in eliminating *Neisseria meningitidis* from the throats of carriers.²² With the more widespread use of this agent for treating invasive *H influenzae* type b disease it would be useful to determine whether it can also eliminate this organism from the throats of patients; if so, it may be an alternative to rifampicin for selected contacts.

This study has emphasised the limitations of antibiotic prophylaxis in preventing *H influenzae* type b disease. A significant impact on its incidence can be achieved only by immunisation,²³ which should be introduced as soon as possible for protection of children at risk.

1 Filice GA, Andrews JS, Hudgins MP, Fraser DW. Spread of *Haemophilus influenzae* type b in household contacts of patients with *H influenzae* meningitis. *Am J Dis Child* 1978;132:578-9.

2 Ward JI, Fraser DW, Baraff LJ, Plikaytis BD. *Haemophilus influenzae* meningitis. A national study of secondary spread in household contacts. *N Engl J Med* 1979;301:122-6.

- 3 Glode MP, Daum RS, Goldmann DA, Leclair J, Smith A. *Haemophilus influenzae* type b meningitis: a contagious disease of children. *BMJ* 1990;280:899-901.
- 4 Campbell LR, Zedd AJ, Michaels RH. Household spread of infection due to *Haemophilus influenzae* type b. *Pediatrics* 1980;66:115-7.
- 5 Glode MP, Daum RS, Boies EG, Ballard TL, Murray M, Granoff DM. Effect of rifampicin chemoprophylaxis on carriage eradication and new acquisition of *Haemophilus influenzae* type b contacts. *Pediatrics* 1985;76:537-42.
- 6 Band JD, Fraser DW, Ajello G. Prevention of *Haemophilus influenzae* type b disease. *JAMA* 1984;251:2381-6.
- 7 Centers for Disease Control. Prevention of secondary cases of *Haemophilus influenzae* type b disease. *MMWR* 1982;31:672-4, 679-80.
- 8 American Academy of Pediatrics, Committee on Infectious Diseases. Revision of recommendation for use of rifampicin prophylaxis of contacts of patients with *Haemophilus influenzae* infection. *Pediatrics* 1984;74:301-2.
- 9 Bodies EG, Granoff DM, Squires JE, Barenkamp SJ. Development of *Haemophilus influenzae* type b meningitis in a household contact treated with rifampicin. *Pediatrics* 1982;70:141-2.
- 10 Murphy TV, McCracken GH, Zweighaft TC, Hansen EJ. Emergence of rifampicin-resistant *Haemophilus influenzae* after prophylaxis. *J Pediatr* 1981;99:406-9.
- 11 Michaels RH, Norden CW. Pharyngeal colonization with *Haemophilus influenzae* type b: a longitudinal study of families with a child with meningitis or epiglottitis due to *H influenzae* type b. *J Infect Dis* 1977;136:2228.
- 12 Daum RS, Glode MP, Goldmann DA, et al. Rifampicin chemoprophylaxis for household contacts of patients with invasive infections due to *Haemophilus influenzae* type b. *J Pediatr* 1981;98:485-91.
- 13 Gilsdorf JR. Dynamics of nasopharyngeal colonization with *Haemophilus influenzae* type b during antibiotic therapy. *Pediatrics* 1986;77:242-5.
- 14 Apert GA, Campos JM, Smith DR, Barenkamp SJ, Fleisher GR. Incidence and persistence of *Haemophilus influenzae* type b upper airway colonization in patients with meningitis. *J Pediatr* 1985;107:555-7.
- 15 Gilbert GL, Clements DA, Broughton AJ. *Haemophilus influenzae* type b infections in Victoria, Australia, 1985-1987. *Pediatr Infect Dis J* 1990;9:252-7.
- 16 Michaels RH, Stonebraker FE, Robbins JB. Use of antiserum agar for detection of *Haemophilus influenzae* type b in the pharynx. *Pediatr Res* 1975;9:513-6.
- 17 Gilbert GL. Epidemiology and prevention of invasive *Haemophilus influenzae* type b infection. *Aust Paediatr J* 1987;23:323-7.
- 18 Gilbert GL. Antibiotic prophylaxis for contacts of patients with invasive infection due to *Haemophilus influenzae* type b. Australian College of Paediatrics Newsletter, May, 1987.
- 19 Michaels RH, Poziviak CS, Stonebraker FE, Norden CW. Factors affecting pharyngeal *Haemophilus influenzae* type b colonization rates in children. *J Clin Microbiol* 1976;4:413-7.
- 20 Li KI, Wald ER. Use of rifampicin in *Haemophilus influenzae* type b infections. *Am J Dis Child* 1986;140:381-5.
- 21 Shapiro ED, Wald ER. Efficacy of rifampicin in eliminating pharyngeal carriage of *Haemophilus influenzae* type b. *Pediatr* 1980;66:5-8.
- 22 Schwartz B, Al-Tobaiki A, Al-Ruwais, et al. Comparative efficacy of ceftriaxone and rifampicin in eradicating pharyngeal carriage of group A *Neisseria meningitidis*. *Lancet* 1988;i:1239-42.
- 23 Clements DA, Gilbert GL. Immunization for prevention of *Haemophilus influenzae* type b infection: a review. *Aust NZ J Med* 1990;20:828-34.

(Accepted 12 April 1991)

Audit of an official recommendation on screening for congenital dislocation of the hip

Dai Anthony Jones, Dawn Beynon,
B N C Littlepage

Guidance on screening for congenital dislocation of the hip has been given by the Standing Medical Advisory Committee for the Central Health Services Council, which reported in 1966 and 1969.¹ In 1986 this advice was updated.² The booklet was made widely available and also stimulated editorials and special articles in leading medical journals.^{3,4} This report was published against a background of doubt that screening was effective and also evidence that the incidence of late cases was increasing despite screening.⁵

The 1986 recommendations recognised that several health professionals may take part in the screening process, and therefore recommended that "A designated officer within each Health District should keep the whole Screening programme under review and record and evaluate the incidence of cases detected late—such information should be made available to the health professionals concerned." Although the term "audit" was not widely used at the time, it is clear that this is what was being proposed—that is, feedback of the

failures of the process of screening and modification of the process accordingly. We assessed the effectiveness of the distribution of the recommendation and its level of implementation.

Methods and results

A questionnaire was sent to each health district in the United Kingdom. Out of a wide range of questions asked, two were: "Have you identified a designated officer within your district to keep the whole screening programme under review?" and "Does any paediatrician or orthopaedic surgeon in your district have a special interest in congenital dislocation of the hip? (Please name.)"

Of the 216 questionnaires distributed, 152 health districts replied (70%). Only 67 (45%) of these health districts had appointed a designated officer to oversee the screening process. Of the 150 replies, 95 named clinicians who had a special interest in congenital dislocation of the hip: 75 were orthopaedic surgeons, 13 were paediatricians, one was a community physician, and the others quoted a combination of specialties.

Comment

The revised memorandum on screening for congenital dislocation of the hip was widely circulated to professional groups and health authorities accompanied by a letter from the chief medical officer or chief nursing officer (C190(86)17, CNO(86)13). A press

West Glamorgan Health Authority, Swansea SA1 5AQ

Dai Anthony Jones, FRCS,
orthopaedic surgeon
Dawn Beynon, CHSM, senior
administrator
B N C Littlepage, FFCMI,
chief administrative medical
officer

Correspondence to:
Mr D A Jones, Department
of Orthopaedics, Morriston
Hospital, Swansea
SA6 6NL.

BMJ 1991;302:1435-6